Interestingly, as exploratory analysis, the trial focused also on the tumor microenvironment (TME), on the changes induced in it by vascular endothelial growth factor (VEGF) and targeted therapy against VEGF receptor (VEGFR), able to convert a “cold” tumor, such as HCC, into an “immunologically hot” one [12]. This evidence concerns the gene KDR and hepatocellular carcinoma.